{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:46:51Z","timestamp":1787161611464,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ajo.2025.12.025","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T16:32:05Z","timestamp":1766766725000},"page":"66-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Association of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists With Risk of Cataract"],"prefix":"10.1016","volume":"284","author":[{"given":"Bing-Hua","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Han","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lien-Chen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Pin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jie","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hsien","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10374","key":"10.1016\/j.ajo.2025.12.025_bib0001","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(22)01839-6","article-title":"Cataracts","volume":"401","author":"Cicinelli","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.ajo.2025.12.025_bib0002","doi-asserted-by":"crossref","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators; Vision Loss Expert Group of the GlobalBurden of Disease Study. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the right to sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144-e160. doi:10.1016\/s2214-109x(20)30489-7.","DOI":"10.1016\/S2214-109X(20)30489-7"},{"issue":"9459","key":"10.1016\/j.ajo.2025.12.025_bib0003","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0140-6736(05)70803-5","article-title":"Age-related cataract","volume":"365","author":"Asbell","year":"2005","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ajo.2025.12.025_bib0004","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s41433-020-0806-3","article-title":"Global and regional prevalence of age-related cataract: a comprehensive systematic review and meta-analysis","volume":"34","author":"Hashemi","year":"2020","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.1016\/j.ajo.2025.12.025_bib0005","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s10384-010-0817-x","article-title":"Etiology of ocular diseases in elderly Amis aborigines in Eastern Taiwan (The Amis Eye Study)","volume":"54","author":"Huang","year":"2010","journal-title":"Jpn J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2025.12.025_bib0006","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.ophtha.2005.02.015","article-title":"Prevalence of cataract in rural Indonesia","volume":"112","author":"Husain","year":"2005","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2025.12.025_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094189","article-title":"Prevalence of and factors associated with lens opacities in a Korean adult population with and without diabetes: the 2008-2009 Korea National Health and Nutrition Examination Survey","volume":"9","author":"Kim","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.ajo.2025.12.025_bib0008","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1167\/iovs.03-0011","article-title":"Lens opacities in a rural population of Southern India: the Aravind Comprehensive Eye Study","volume":"44","author":"Nirmalan","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.12.025_bib0009","article-title":"Diabetic cataract-pathogenesis, epidemiology and treatment","volume":"2010","author":"Pollreisz","year":"2010","journal-title":"J Ophthalmol"},{"issue":"suppl 3","key":"10.1016\/j.ajo.2025.12.025_bib0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/dom.15700","article-title":"Current type 2 diabetes guidelines: individualized treatment and how to make the most of metformin","volume":"26","author":"Chan","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.ajo.2025.12.025_bib0011","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/dmrr.2407","article-title":"Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis","volume":"29","author":"Maeda","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"10.1016\/j.ajo.2025.12.025_bib0012","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.diabet.2015.02.003","article-title":"Antidiabetic agents: potential anti-inflammatory activity beyond glucose control","volume":"41","author":"Scheen","year":"2015","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ajo.2025.12.025_bib0013","article-title":"Relationship between SGLT-2i and ocular diseases in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.ajo.2025.12.025_bib0014","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ophtha.2024.08.023","article-title":"Comparative effects of glucagon-like peptide 1 receptor agonists and metformin on glaucoma risk in patients with type 2 diabetes","volume":"132","author":"Muayad","year":"2025","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2025.12.025_bib0015","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00592-023-02087-y","article-title":"Diabetic patients with and without sodium-glucose cotransporter-2 inhibitors use and cataract risk: real-world observational investigation","volume":"60","author":"Hu","year":"2023","journal-title":"Acta Diabetol"},{"issue":"7","key":"10.1016\/j.ajo.2025.12.025_bib0016","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ophtha.2025.01.016","article-title":"Glucagon-like peptide-1 receptor agonist impact on chronic ocular disease including age-related macular degeneration","volume":"132","author":"Allan","year":"2025","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2025.12.025_bib0017","doi-asserted-by":"crossref","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"3","key":"10.1016\/j.ajo.2025.12.025_bib0018","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.bbrc.2009.12.075","article-title":"Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression","volume":"391","author":"Ishibashi","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.ajo.2025.12.025_bib0019","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/jcp.26760","article-title":"Sodium\u2013glucose cotransporter inhibitors and oxidative stress: an update","volume":"234","author":"Yaribeygi","year":"2019","journal-title":"J Cell Physiol"},{"issue":"10","key":"10.1016\/j.ajo.2025.12.025_bib0020","first-page":"1506","article-title":"Age-related changes in the kinetics of human lenses: prevention of the cataract","volume":"9","author":"Pescosolido","year":"2016","journal-title":"Int J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2025.12.025_bib0021","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s00417-002-0616-2","article-title":"Advanced glycation endproducts in human diabetic and non-diabetic cataractous lenses","volume":"241","author":"Pokupec","year":"2003","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2025.12.025_bib0022","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/bjo.85.6.746","article-title":"Advanced glycation: an important pathological event in diabetic and age related ocular disease","volume":"85","author":"Stitt","year":"2001","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2025.12.025_bib0023","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000316481","article-title":"Oxidative damage and the prevention of age-related cataracts","volume":"44","author":"Beebe","year":"2010","journal-title":"Ophthalmic Res"},{"issue":"1","key":"10.1016\/j.ajo.2025.12.025_bib0024","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3164734","article-title":"The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults","volume":"2016","author":"Nita","year":"2016","journal-title":"Oxid Med Cell Longev"},{"issue":"5","key":"10.1016\/j.ajo.2025.12.025_bib0025","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.exer.2004.12.007","article-title":"Age-related nuclear cataract\u2014oxidation is the key","volume":"80","author":"Truscott","year":"2005","journal-title":"Exp Eye Res"},{"issue":"3","key":"10.1016\/j.ajo.2025.12.025_bib0026","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pathophys.2006.05.006","article-title":"Oxidative stress in cataracts","volume":"13","author":"Vinson","year":"2006","journal-title":"Pathophysiology"},{"issue":"10","key":"10.1016\/j.ajo.2025.12.025_bib0027","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.ajo.2025.12.025_bib0028","first-page":"4646","article-title":"Glucose transport in the lens","volume":"43","author":"Smith","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.ajo.2025.12.025_bib0029","doi-asserted-by":"crossref","first-page":"7299","DOI":"10.1111\/dom.70131","article-title":"Impact of SGLT2 inhibitors on the risk of age-related ocular diseases in patients with type 2 diabetes mellitus: a target trial emulation study","volume":"27","author":"Lee","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.ajo.2025.12.025_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089923","article-title":"Body mass index and risk of age-related cataract: a meta-analysis of prospective cohort studies","volume":"9","author":"Ye","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ajo.2025.12.025_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.4182","article-title":"Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US","volume":"2","author":"Eberly","year":"2021","journal-title":"JAMA Health Forum"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425006877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425006877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T08:21:00Z","timestamp":1781857260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425006877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":31,"alternative-id":["S0002939425006877"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.12.025","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists With Risk of Cataract","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}